Actively Recruiting
Phase 3 Study to Assess Safety and Immune Response of Sinovacs 13-Valent Pneumococcal Vaccine in Healthy Infants and Young Children Aged 6 Weeks to 5 Years
Led by Sinovac Life Sciences Co., Ltd. · Updated on 2026-01-28
3080
Participants Needed
1
Research Sites
11 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of a 13-valent pneumococcal conjugate vaccine PCV13 developed by Sinovac Life Science Co., Ltd in children aged 2 months to 5 years. This Phase 3 randomized, double-blind, active-controlled clinical trial compares Sinovac PCV13 with the currently used vaccine, Prevnar 13. The study aims to understand how well Sinovac PCV13 stimulates the immune system and how safe it is for young children. Participants aged 6 weeks to 5 years will receive four doses of either Sinovac PCV13 or Prevnar 13 following different immunization schedules. Each dose is 0.5 mL given as an intramuscular injection. The trial includes two groups one receiving the Sinovac vaccine and the other receiving the active control vaccine. The study is designed to monitor responses after both the primary vaccination series and booster doses. Throughout the study, children will undergo assessments to measure antibody levels specific to pneumococcal bacteria 30 days after primary and booster vaccinations. Safety will be monitored within 30 days after each dose and for six months after the final dose. Guardians will provide consent and remain in contact to support study procedures. The study will last until July 2026, ensuring thorough evaluation of immune response and vaccine safety in this pediatric population.
CONDITIONS
Brief Title
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
Research Team
Y
Yanxia Wang
X
Xiaoqiang Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here